The fact that we observed that androgen treatment lowered the protein expression of BCl-2 and P53 in 104-R1 and 104-R2 cells (Figure 4) may strengthen the rationale of using androgen as a treatment for advanced prostate cancers. Here, TP53 is linked to prostate carcinoma.